Clinical Trial: Dosing of Amicar and Measure of Fibrinolysis by TEG During Cardiac Surgery

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: The Effect of Standard vs Aggressive Dosing Regimens for Epsilon-aminocaproic Acid on a Quantifiable Parameter of Fibrinolysis as Measured by Thromboelastography

Brief Summary: This study hopes to determine the optimal antifibrinolytic dosing to decrease bleeding and blood transfusion after cardiac surgery without increasing adverse events

Detailed Summary:
Sponsor: University of Pennsylvania

Current Primary Outcome: degree of fibrinolysis as measured by thromboelastography [ Time Frame: Length of cardiac surgery ]

The primary objective of the study will be to determine if a change in EACA dosing for cardiac surgery cases involving circulatory arrest actually leads to a quantifiable change in the degree of fibrinolysis as measured by TEG.


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: University of Pennsylvania

Dates:
Date Received: October 16, 2013
Date Started: January 2013
Date Completion:
Last Updated: August 18, 2016
Last Verified: August 2016